News

April 12, 2023
Represented Everi Holdings Inc. in Deal to Acquire Assets of Video King, April 12, 2023, Press Release. Pillsbury Represents Everi in Deal to Acquire Assets of Video King

March 27, 2023
Advised Sumitomo Chemical Co., Ltd. on Purchase of Biorational Leader FBSciences, Holdings, Inc., March 27, 2023, Press Release. Pillsbury Advises Sumitomo Chemical on Purchase of Biorational Leader FBSciences

January 20, 2023
2022 Americas M&A Atlas Award for Representation of LifeSpeak’s in the Acquisition of Wellbeats, January 20, 2023, Press Release. Pillsbury-Led M&A Deals Receive Recognition at 2022 Americas M&A Atlas Awards

February 15, 2022
Represented LifeSpeak Inc. in its $92.5 Million Acquisition of Wellbeats, Inc., February 15, 2022, Press Release. Pillsbury Advises LifeSpeak in Acquisition of Wellbeats

February 9, 2022
Advised SecurityScorecard in its Acquisition of LIFARS, LLC, February 9, 2022, Press Release. Pillsbury Advises SecurityScorecard in Acquisition of Cybersecurity Company LIFARS

December 2, 2021
Represented the Estancia La Jolla Hotel & Spa in its $108 Million Acquisition by Pebblebrook Hotel Trust, December 2, 2021, Press Release. Pillsbury Represents Seller of Estancia La Jolla Hotel & Spa in $108 Million Deal

July 27, 2021
Represented Antibody and Reagent Leader BioLegend in its $5.25 Billion Acquisition by Perkin Elmer, July 27, 2021, Press Release. Pillsbury Representing Antibody and Reagent Leader BioLegend in its $5.25 Billion Acquisition by PerkinElmer

January 12, 2021
Handled Intellectual Property Due Diligence for REGENXBIO and Nektar in Agreements with HCR Valuing Over $350 Million, January 12, 2021, Press Release. Pillsbury Handles IP Due Diligence for REGENXBIO and Nektar in Agreements with HCR Valuing Over $350 Million

November 13, 2020
Advised CUBEX in Acquisition of Medical Business Assets by BD (Becton, Dickinson and Company), November 13, 2020, Press Release. Pillsbury Advises CUBEX in Acquisition of Medical Business Assets by BD

November 3, 2020
Provided Intellectual Property Diligence for $575 Million Royalty Sale for Cystic Fibrosis Foundation, November 3, 2020, Press Release. Pillsbury Provides IP Due Diligence For $575 Million Royalty Sale

June 5, 2020
Led Plus Therapeutics in Licensing Transaction, June 5, 2020, Press Release.Pillsbury Leads Plus Therapeutics in Licensing Transaction